NASDAQ:AFMD - Affimed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.47 -0.01 (-0.29 %)
(As of 02/15/2019 03:55 PM ET)
Previous Close$3.48
Today's Range$3.46 - $3.50
52-Week Range$1.40 - $7.35
Volume9,268 shs
Average Volume294,838 shs
Market Capitalization$216.49 million
P/E Ratio-4.47
Dividend YieldN/A
Beta3.42
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2165-3070

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.27 million
Book Value$0.80 per share

Profitability

Net Income$-34,160,000.00
Net Margins-2,124.72%

Miscellaneous

Employees8,406
Market Cap$216.49 million
OptionableOptionable

Affimed (NASDAQ:AFMD) Frequently Asked Questions

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) issued its earnings results on Wednesday, May, 17th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.03. The biopharmaceutical company had revenue of $1.94 million for the quarter, compared to analysts' expectations of $1.73 million. Affimed had a negative net margin of 2,124.72% and a negative return on equity of 82.22%. The business's revenue for the quarter was up 385.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.25) EPS. View Affimed's Earnings History.

When is Affimed's next earnings date?

Affimed is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for Affimed.

What price target have analysts set for AFMD?

3 brokerages have issued twelve-month price targets for Affimed's shares. Their predictions range from $4.00 to $5.00. On average, they expect Affimed's stock price to reach $4.6667 in the next year. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for Affimed.

What is the consensus analysts' recommendation for Affimed?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.

Has Affimed been receiving favorable news coverage?

Media coverage about AFMD stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Affimed earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next few days.

Who are some of Affimed's key competitors?

Who are Affimed's key executives?

Affimed's management team includes the folowing people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

Who are Affimed's major shareholders?

Affimed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Carmignac Gestion (3.43%), Stonepine Capital Management LLC (1.14%), Telemetry Investments L.L.C. (0.68%), Eversept Partners LP (0.54%), Prescott Group Capital Management L.L.C. (0.31%) and Bellevue Group AG (0.27%).

Which institutional investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Carmignac Gestion and Knott David M.

Which institutional investors are buying Affimed stock?

AFMD stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Telemetry Investments L.L.C., Bellevue Group AG, Keybank National Association OH, FDx Advisors Inc., Prescott Group Capital Management L.L.C., Barclays PLC and Geode Capital Management LLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $3.47.

How big of a company is Affimed?

Affimed has a market capitalization of $216.49 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 8,406 workers across the globe.

What is Affimed's official website?

The official website for Affimed is http://www.affimed.com.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]


MarketBeat Community Rating for Affimed (NASDAQ AFMD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Featured Article: Put Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel